Portfolio Update

4 April 2007 FINSBURY EMERGING BIOTECHNOLOGY TRUST PLC (the "Company") QUARTERLY STATEMENT OF INVESTMENTS In compliance with the Listing Rules - Chapter 21 Investment Entities (I)(ii), the Company discloses the following: * Investments valuing greater than 5% of the Company's gross assets comprise the following: Company Name Value of Investment % of Total at Portfolio Assets 31 March 2007 GILEAD SCIENCES INC COM USD0.001 5,262,064 6.82 AMGEN COM USD0.0001 5,165,417 6.70 GENENTECH INC COM STK USD0.02 NPV 4,852,678 6.29 GENZYME CORP GENERAL DIVISION COM USD0.01 4,159,013 5.39 * The ten largest investments held by the Company comprise the following: Company Name Value of Investment % of Total at Portfolio Assets 31 March 2007 GILEAD SCIENCES INC COM USD0.001 5,262,064 6.82 AMGEN COM USD0.0001 5,165,417 6.70 GENENTECH INC COM STK USD0.02 NPV 4,852,678 6.29 GENZYME CORP GENERAL DIVISION COM USD0.01 4,159,013 5.39 MEDIMMUNE INC COM USD0.01 3,559,344 4.61 CUBIST PHARMACEUTICALS COM STK USD0.001 2,850,080 3.69 BIOGEN IDEC COM USD0.0005 2,643,215 3.43 ONYX PHARMACEUTICALS COM USD0.001 2,534,216 3.28 INDEVUS PHARMACEUTICALS INC USD0.001 2,402,707 3.11 VION PHARMACEUTICALS COM USD0.01 2,326,459 3.02 - ENDS - For further information please contact: Tracey Lago, Senior Company Secretary Close Investments Limited Telephone: 020 7426 6219
UK 100

Latest directors dealings